Article · 2017
Editorial Board Member
Arik Dahan
Professor, Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University, Israel
About
As published by the journal they serve.
Arik Dahan is an Assistant Professor of Pharmaceutics and Biopharmaceutics at the Department of Clinical Pharmacology and the School of Pharmacy, Ben-Gurion University of the Negev in Beer-Sheva, Israel. He is also an Adjunct Professor of Pharmaceutical Sciences at the College of Pharmacy, University of Michigan. Dr. Dahan received his Ph.D. (2007) from the Hebrew University of Jerusalem. He was a Post-Doctoral Research Fellow at the University of Michigan (2007-2010) with Professor Gordon L. Amidon. Dr. Dahans research interest is the integration of up-to-date molecular/cellular mechanistic investigations of drug disposition in the context of the human body. In implementing this molecular biopharmaceutical approach to ADME research, Dr. Dahan is seeking to enable mechanistic-based successful solutions to drug delivery/therapy, in challenging scenarios e.g. low-solubility, low-permeability, extensive metabolism, poor site targeting, various pathophysiological conditions, and pediatrics. He has published over 50 top-notch Journal papers, and contributed chapters to 6 books.
Research interests
Journals they serve
The seats these journals name them in.
- Pharmaceutica Analytica ActaEditorial Board Member
Articles we hold
Articles in the journals they serve whose byline carries this name.
Article · 2017
Developing better formulations for oral lipophilic drugs by accounting for both the solubility and the intestinal permeability
Article · 2017
The complexity of intestinal permeability and its implications on oral drug absorption and bioavailablity
Article · 2017
Developing better formulations for oral lipophilic drugs by accounting for both the solubility and the intestinal permeability
Article · 2017
Phospholipid-based prodrugs for the treatment of IBD: Drug targeting strategy
Article · 2016
The solubility-permeability interplay and formulation development of low-solubility drugs
Article · 2016
The solubility-permeability interplay in Formulation Development for Low-Solubility Drugs
Article · 2016
Implications of Segmental-Dependent Intestinal Permeability in Oral Drug Delivery
Article · 2016
Amorphous solid dispersion (ASD)formulation of the low-solubility drug rifaximine allows overcoming the solubility-permeability tradeoff
Article · 2016
Implications of segmental-dependent intestinal permeability in oral drug delivery
Article · 2016
Implications of segmental-dependent intestinal permeability in oral drug delivery
This page holds what the journals publish about this profile: no contact details, and nothing gathered from anywhere else. Ask us to correct or remove this profile.
